• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Lewis C. Cantley, PhD


  • Shinoda G, Shyh-Chang N, de Soysa TY, Zhu H, Seligson MT, Shah SP, Abo-Sido N, Yabuuchi A, Hagan JP, Gregory RI, Asara JM, Cantley LC, Moss EG, Daley GQ.Fetal Deficiency of Lin28 Programs Life-Long Aberrations in Growth and Glucose Metabolism.Stem Cells. 2013 May 10.
  • Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, Henske EP, Haigis MC, Cantley LC, Stephanopoulos G, Yu J, Blenis J.The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.Cell. 2013 May 9;153(4):840-54.
  • Bettaieb A, Bakke J, Nagata N, Matsuo K, Xi Y, Liu S, Aboubechara D, Melhem R, Stanhope K, Cummings B, Graham J, Bremer A, Zhang S, Lyssiotis CA, Zhang ZY, Cantley LC, Havel PJ, Haj FG.Protein-Tyrosine Phosphatase 1B Regulates Pyruvate Kinase M2 Tyrosine Phosphorylation.J Biol Chem. 2013 May 2.
  • Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, Cantley LC, Heiden MG, Vitkup D.Heterogeneity of tumor-induced gene expression changes in the human metabolic network.Nat Biotechnol. 2013 Apr 21.
  • Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.A colorectal cancer classification system that associates cellular phenotype and responses to therapy.Nat Med. 2013 Apr 14.
  • Gallop JL, Walrant A, Cantley LC, Kirschner MW.Phosphoinositides and membrane curvature switch the mode of actin polymerization via selective recruitment of toca-1 and Snx9.Proc Natl Acad Sci U S A. 2013 Apr 15.
  • Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, Depinho RA, Cantley LC, Kimmelman AC.Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.Nature. 2013 Mar 27.
  • Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE, Kahn BB, Cantley LC.AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1.Mol Cell. 2013 Mar 28;49(6):1167-75.
  • Carracedo A, Cantley LC, Pandolfi PP.Cancer metabolism: fatty acid oxidation in the limelight.Nat Rev Cancer. 2013 Apr;13(4):227-32.
  • Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa KS, Brown V, Signoretti S, Soltoff SP, Cantley LC.Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3483-8.
  • Davis MI, Sasaki AT, Shen M, Emerling BM, Thorne N, Michael S, Pragani R, Boxer M, Sumita K, Takeuchi K, Auld DS, Li Z, Cantley LC, Simeonov A.A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation.PLoS ONE. 2013;8(1):e54127.
  • Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, Zhang J, Onder T, Unternaehrer JJ, Zhu H, Asara JM, Daley GQ, Cantley LC.Influence of threonine metabolism on S-adenosylmethionine and histone methylation.Science. 2013 Jan 11;339(6116):222-6.
  • Baker R, Lewis SM, Sasaki AT, Wilkerson EM, Locasale JW, Cantley LC, Kuhlman B, Dohlman HG, Campbell SL.Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function.Nat Struct Mol Biol. 2013 Jan;20(1):46-52.
  • Lyssiotis CA, Cantley LC.SIRT6 puts cancer metabolism in the driver's seat.Cell. 2012 Dec 7;151(6):1155-6.
  • Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z.ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.Nat Cell Biol. 2012 Dec;14(12):1295-304.
  • Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills GB, Cantley LC, Chin L.Somatic Mutations of PIK3R1 Promote Gliomagenesis.PLoS ONE. 2012;7(11):e49466.
  • Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer.Cancer Discovery. 2012 Nov;2(11):1048-63.
  • Kim SG, Hoffman GR, Poulogiannis G, Buel GR, Jang YJ, Lee KW, Kim BY, Erikson RL, Cantley LC, Choo AY, Blenis J.Metabolic Stress Controls mTORC1 Lysosomal Localization and Dimerization by Regulating the TTT-RUVBL1/2 Complex.Mol Cell. 2012 Nov 6.
  • Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS.AACR Cancer Progress Report 2012.Clin Cancer Res. 2012 Nov 1;18(21 Suppl):S1-100.
  • Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, DeLaBarre B, Cianchetta G, Sethumadhavan S, Wang X, Yan S, Gao Y, Fang C, Wei W, Jiang F, Wang S, Qian K, Saunders J, Driggers E, Woo HK, Kunii K, Murray S, Yang H, Yen K, Liu W, Cantley LC, Vander Heiden MG, Su SM, Jin S, Salituro FG, Dang L.Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.Chem Biol. 2012 Sep 21;19(9):1187-98.
  • Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG.Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.Nat Chem Biol. 2012 Aug 26.
  • Myers AP, Cantley LC.Sugar free, cancer free?.Nutrition. 2012 Oct;28(10):1036.
  • Hutti JE, Porter MA, Cheely AW, Cantley LC, Wang X, Kireev D, Baldwin AS, Janzen WP.Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε.PLoS ONE. 2012;7(7):e41494.
  • Marinis JM, Hutti JE, Homer CR, Cobb BA, Cantley LC, McDonald C, Abbott DW.IκB kinase α phosphorylation of TRAF4 downregulates innate immune signaling.Mol Cell Biol. 2012 Jul;32(13):2479-89.
  • Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, Haviv S, Asara JM, Pandolfi PP, Cantley LC.Ubiquitination of k-ras enhances activation and facilitates binding to select downstream effectors.Sci Signal. 2011;4(163):ra13.
  • Yuan TL, Wulf G, Burga L, Cantley LC.Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations.Curr Biol. 2011 Feb 8;21(3):173-83.
  • Locasale JW, Vander Heiden MG, Cantley LC.Rewiring of glycolysis in cancer cell metabolism.Cell Cycle. 2010 Nov 1;9(21):4253.
  • Yuan TL, Cantley LC.Introduction.Curr Top Microbiol Immunol. 2011;346:1-7.
  • Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S.Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.Br J Cancer. 2010 Sep 28;103(7):1025-33.
  • Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC.Evidence for an alternative glycolytic pathway in rapidly proliferating cells.Science. 2010 Sep 17;329(5998):1492-9.
  • Myers AP, Cantley LC.Targeting a common collaborator in cancer development.Sci Transl Med. 2010 Sep 8;2(48):48ps45.
  • Engelman JA, Cantley LC.Chemoprevention meets glucose control.Cancer Prev Res (Phila Pa). 2010 Sep;3(9):1049-52.
  • Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ.PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15145-50.
  • Moritz A, Li Y, Guo A, Villén J, Wang Y, MacNeill J, Kornhauser J, Sprott K, Zhou J, Possemato A, Ren JM, Hornbeck P, Cantley LC, Gygi SP, Rush J, Comb MJ.Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.Sci Signal. 2010;3(136):ra64.
  • Locasale JW, Cantley LC.Altered metabolism in cancer.BMC Biol. 2010;8:88.
  • Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR.The Phosphoinositide 3-Kinase Regulatory Subunit p85{alpha} Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling.Cancer Res. 2010 Jul 1;70(13):5305-15.
  • Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature. 2010 Jun 17;465(7300):966.
  • Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM.A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11002-7.
  • Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, Cantley LC, Blenis J.Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.Mol Cell. 2010 May 28;38(4):487-99.
  • Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ.Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.PLoS ONE. 2010;5(5):e10504.
  • Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.Bioorg Med Chem Lett. 2010 Jun 1;20(11):3387-93.
  • Takeuchi H, Takeuchi T, Gao J, Cantley LC, Hirata M.Characterization of PXK as a protein involved in epidermal growth factor receptor trafficking.Mol Cell Biol. 2010 Apr;30(7):1689-702.
  • Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.Identification of small molecule inhibitors of pyruvate kinase M2.Biochem Pharmacol. 2010 Apr 15;79(8):1118-24.
  • Wong KK, Engelman JA, Cantley LC.Targeting the PI3K signaling pathway in cancer.Curr Opin Genet Dev. 2010 Feb;20(1):87-90. Review.
  • Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR.The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism.Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1894-9.
  • Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ.Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.J Med Chem. 2010 Feb 11;53(3):1048-55.
  • Shiga K, Takayama K, Futaki S, Hutti JE, Cantley LC, Ueki K, Ono Y, Mukai H.Development of an intracellularly acting inhibitory peptide selective for PKN.Biochem J. 2010 Jan 15;425(2):445-543.
  • Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature. 2009 Dec 10;462(7274):739-44.
  • Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.Sci Signal. 2009;2(97):ra73.
  • Smith RA, Yuan H, Weissleder R, Cantley LC, Josephson L.A wortmannin-cetuximab as a double drug.Bioconjug Chem. 2009 Nov;20(11):2185-9.
  • Myers AP, Meyerhardt JA, Cantley LC.Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?.Clin Cancer Res. 2009 Nov 15;15(22):6748-50.
  • Hill JW, Xu Y, Preitner F, Fukuda M, Cho YR, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB, Zhao JJ, Elmquist JK.Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis.Endocrinology. 2009 Nov;150(11):4874-82.
  • Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR.Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.Biochem J. 2009 Nov 15;424(1):47-60.
  • Locasale JW, Cantley LC, Vander Heiden MG.Cancer's insatiable appetite.Nat Biotechnol. 2009 Oct;27(10):916-7.
  • Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP.Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha.Dev Dyn. 2009 Oct;238(10):2670-9.
  • Cantley LC.Lewis C. Cantley.Curr Biol. 2009 Jul 28;19(14):R540-1.
  • Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC.Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.Cancer Cell. 2009 Aug 4;16(2):115-25.
  • Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo JL, Weissleder R, Kohler R, Yaffe MB, Cantley LC, Josephson L.The antiproliferative cytostatic effects of a self-activating viridin prodrug.Mol Cancer Ther. 2009 Jun;8(6):1666-75.
  • Hutti JE,Shen RR,Abbott DW,Zhou AY,Sprott KM,Asara JM,Hahn WC,Cantley LC.Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.Mol Cell. 2009 May 14;34(4):461-72.
  • Vander Heiden MG,Cantley LC,Thompson CB.Understanding the Warburg effect: the metabolic requirements of cell proliferation.Science. 2009 May 22;324(5930):1029-33. Review.
  • Ogino S,Nosho K,Kirkner GJ,Shima K,Irahara N,Kure S,Chan AT,Engelman JA,Kraft P,Cantley LC,Giovannucci EL,Fuchs CS.PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.J Clin Oncol. 2009 Mar 20;27(9):1477-84.
  • Nicklin P,Bergman P,Zhang B,Triantafellow E,Wang H,Nyfeler B,Yang H,Hild M,Kung C,Wilson C,Myer VE,MacKeigan JP,Porter JA,Wang YK,Cantley LC,Finan PM,Murphy LO.Bidirectional transport of amino acids regulates mTOR and autophagy.Cell. 2009 Feb 6;136(3):521-34.
  • Zheng B,Jeong JH,Asara JM,Yuan YY,Granter SR,Chin L,Cantley LC.Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.Mol Cell. 2009 Jan 30;33(2):237-47.
  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garca-Echeverra C, Weissleder R, Mahmood U, Cantley LC, Wong KK.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.Nat Med. 2008 Dec;14(12):1351-6.
  • Shaywitz AJ,Courtney KD,Patnaik A,Cantley LC.PI3K enters beta-testing.Cell Metab. 2008 Sep;8(3):179-81. Review.
  • Carracedo A,Ma L,Teruya-Feldstein J,Rojo F,Salmena L,Alimonti A,Egia A,Sasaki AT,Thomas G,Kozma SC,Papa A,Nardella C,Cantley LC,Baselga J,Pandolfi PP.Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.J Clin Invest. 2008 Sep;118(9):3065-74.
  • Blois J,Yuan H,Smith A,Pacold ME,Weissleder R,Cantley LC,Josephson L.Slow self-activation enhances the potency of viridin prodrugs.J Med Chem. 2008 Aug 14;51(15):4699-707.
  • Yuan TL,Choi HS,Matsui A,Benes C,Lifshits E,Luo J,Frangioni JV,Cantley LC.Class 1A PI3K regulates vessel integrity during development and tumorigenesis.Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9739-44.
  • Engelman JA, Cantley LC.A sweet new role for EGFR in cancer.Cancer Cell. 2008 May;13(5):375-6.
  • Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC.Pyruvate kinase M2 is a phosphotyrosine-binding protein.Nature. 2008 Mar 13;452(7184):181-6.
  • Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.Nature. 2008 Mar 13;452(7184):230-3.
  • Asara JM, Christofk HR, Freimark LM, Cantley LC.A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen.Proteomics. 2008 Mar;8(5):994-9.
  • Esquibies AE, Bazzy-Asaad A, Ghassemi F, Nishio H, Karihaloo A, Cantley LG.VEGF Attenuates Hyperoxic Injury through Decreased Apoptosis in Explanted Rat Embryonic Lung.Pediatr Res. 2008 Jan;63(1):20-5.
  • Lee JY, Engelman JA, Cantley LC.Biochemistry. PI3K charges ahead.Science. 2007 Jul 13;317(5835):206-7.
  • Manning BD, Cantley LC.AKT/PKB signaling: navigating downstream.Cell. 2007 Jun 29;129(7):1261-74. Review.
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jnne PA.MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.Science. 2007 May 18;316(5827):1039-43.
  • Asara JM, Schweitzer MH, Freimark LM, Phillips M, Cantley LC.Protein Sequences from Mastodon and Tyrannosaurus Rex Revealed by Mass Spectrometry.Science. 2007 Apr 13;316(5822):280-285.
  • Asara JM, Zhang X, Zheng B, Maroney LA, Christofk HR, Wu N, Cantley LC.In-gel stable isotope labeling for relative quantification using mass spectrometry.Nat Protoc. 2006;1(1):46-51.
  • Zheng B, Cantley LC.Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase.Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):819-22.
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrs AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jnne PA.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer.J Clin Invest. 2006 Oct;116(10):2695-706.
  • Engelman JA, Luo J, Cantley LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.Nat Rev Genet. 2006 Aug;7(8):606-19. Review.
  • Shaw RJ, Cantley LC.Ras, PI(3)K and mTOR signalling controls tumour cell growth.Nature. 2006 May 25;441(7092):424-30. Review.
  • Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR.Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta.Cell Metab. 2006 May;3(5):343-53.
  • Pendaries C, Tronchre H, Arbibe L, Mounier J, Gozani O, Cantley L, Fry MJ, Gaits-Iacovoni F, Sansonetti PJ, Payrastre B.PtdIns5P activates the host cell PI3-kinase/Akt pathway during Shigella flexneri infection.EMBO J. 2006 Mar 8;25(5):1024-34.
  • Schulze H, Korpal M, Hurov J, Kim SW, Zhang J, Cantley LC, Graf T, Shivdasani RA.Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis.Blood. 2006 May 15;107(10):3868-75.
  • Weiner OD, Rentel MC, Ott A, Brown GE, Jedrychowski M, Yaffe MB, Gygi SP, Cantley LC, Bourne HR, Kirschner MW.Hem-1 complexes are essential for Rac activation, actin polymerization, and myosin regulation during neutrophil chemotaxis.PLoS Biol. 2006 Feb;4(2):e38.
  • Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.Cancer Res. 2005 Dec 1;65(23):10992-1000.
  • Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC.The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.Science. 2005 Dec 9;310(5754):1642-6.
  • Grimm DH, Karihaloo A, Cai Y, Somlo S, Cantley LG, Caplan MJ.Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells.J Biol Chem. 2006 Jan 6;281(1):137-44.
  • Gozani O, Field SJ, Ferguson CG, Ewalt M, Mahlke C, Cantley LC, Prestwich GD, Yuan J.Modification of protein sub-nuclear localization by synthetic phosphoinositides: evidence for nuclear phosphoinositide signaling mechanisms.Adv Enzyme Regul. 2005;45:171-85.
  • Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B.Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.J Biol Chem. 2005 Nov 11;280(45):37489-94.
  • Luo J, Cantley LC.The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.Cell Cycle. 2005 Oct;4(10):1309-12.
  • Karihaloo A, Karumanchi SA, Cantley WL, Venkatesha S, Cantley LG, Kale S.Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion.Mol Cell Biol. 2005 Sep;25(17):7441-8.
  • Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jnne PA.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.
  • Field SJ, Madson N, Kerr ML, Galbraith KA, Kennedy CE, Tahiliani M, Wilkins A, Cantley LC.PtdIns(4,5)P2 functions at the cleavage furrow during cytokinesis.Curr Biol. 2005 Aug 9;15(15):1407-12.
  • Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC.The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.J Cell Biol. 2005 Aug 1;170(3):455-64.
  • Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC.Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10238-43.
  • Keilhack H, David FS, McGregor M, Cantley LC, Neel BG.Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.J Biol Chem. 2005 Sep 2;280(35):30984-93.
  • Kang CM, Abbott DW, Park ST, Dascher CC, Cantley LC, Husson RN.The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape.Genes Dev. 2005 Jul 15;19(14):1692-704.
  • Park J, Hu Y, Murthy TV, Vannberg F, Shen B, Rolfs A, Hutti JE, Cantley LC, Labaer J, Harlow E, Brizuela L.Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation.Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8114-9.
  • Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC.Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.Mol Cell Biol. 2005 Apr;25(7):2593-606.
  • Engelman JA, Jnne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93.
  • Fernandes N, Sun Y, Chen S, Paul P, Shaw RJ, Cantley LC, Price BD.DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM.J Biol Chem. 2005 Apr 15;280(15):15158-64.
  • Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.The LKB1 tumor suppressor negatively regulates mTOR signaling.Cancer Cell. 2004 Jul;6(1):91-9.
  • Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC.The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35.
  • Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR, Brugge JS, Ferguson CG, Payrastre B, Myszka DG, Cantley LC, Wagner G, Divecha N, Prestwich GD, Yuan J.The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor.Cell. 2003 Jul 11;114(1):99-111.
  • Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6.
  • Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC.Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.Mol Cell. 2002 Jul;10(1):151-62.
  • Karpova AY, Trost M, Murray JM, Cantley LC, Howley PM.Interferon regulatory factor-3 is an in vivo target of DNA-PK.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2818-23.
  • Singh VP, Saluja AK, Bhagat L, van Acker GJ, Song AM, Soltoff SP, Cantley LC, Steer ML.Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis.J Clin Invest. 2001 Nov;108(9):1387-95.
  • Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC, Yuan J.The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death.Mol Cell. 2001 Jun;7(6):1307-19.
  • Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP.Cell surface glypicans are low-affinity endostatin receptors.Mol Cell. 2001 Apr;7(4):811-22.
  • Nishikawa K, Sawasdikosol S, Fruman DA, Lai J, Songyang Z, Burakoff SJ, Yaffe MB, Cantley LC.A peptide library approach identifies a specific inhibitor for the ZAP-70 protein tyrosine kinase.Mol Cell. 2000 Oct;6(4):969-74.
  • Frangioni JV, LaRiccia LM, Cantley LC, Montminy MR.Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening.Nat Biotechnol. 2000 Oct;18(10):1080-5.
  • Rittinger K, Budman J, Xu J, Volinia S, Cantley LC, Smerdon SJ, Gamblin SJ, Yaffe MB.Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding.Mol Cell. 1999 Aug;4(2):153-66.
  • Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC.Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.Science. 1999 Jan 15;283(5400):393-7.
  • Parker D, Jhala US, Radhakrishnan I, Yaffe MB, Reyes C, Shulman AI, Cantley LC, Wright PE, Montminy M.Analysis of an activator:coactivator complex reveals an essential role for secondary structure in transcriptional activation.Mol Cell. 1998 Sep;2(3):353-9.
  • Crovello CS, Lai C, Cantley LC, Carraway KL.Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2.J Biol Chem. 1998 Oct 9;273(41):26954-61.
  • Rameh LE, Rhee SG, Spokes K, Kazlauskas A, Cantley LC, Cantley LG.Phosphoinositide 3-kinase regulates phospholipase Cgamma-mediated calcium signaling.J Biol Chem. 1998 Sep 11;273(37):23750-7.
  • Nishikawa K, Toker A, Wong K, Marignani PA, Johannes FJ, Cantley LC.Association of protein kinase Cmu with type II phosphatidylinositol 4-kinase and type I phosphatidylinositol-4-phosphate 5-kinase.J Biol Chem. 1998 Sep 4;273(36):23126-33.
  • Tolias KF, Rameh LE, Ishihara H, Shibasaki Y, Chen J, Prestwich GD, Cantley LC, Carpenter CL.Type I phosphatidylinositol-4-phosphate 5-kinases synthesize the novel lipids phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 5-phosphate.J Biol Chem. 1998 Jul 17;273(29):18040-6.
  • Rameh LE, Tolias KF, Duckworth BC, Cantley LC.A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate.Nature. 1997 Nov 13;390(6656):192-6.
  • Franke TF, Cantley LC.Apoptosis. A Bad kinase makes good.Nature. 1997 Nov 13;390(6656):116-7.
  • Duckworth BC, Cantley LC.Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence on signal strength.J Biol Chem. 1997 Oct 31;272(44):27665-70.
  • Rameh LE, Arvidsson A, Carraway KL, Couvillon AD, Rathbun G, Crompton A, VanRenterghem B, Czech MP, Ravichandran KS, Burakoff SJ, Wang DS, Chen CS, Cantley LC.A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains.J Biol Chem. 1997 Aug 29;272(35):22059-66.
  • Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK.Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.Science. 1997 Jun 20;276(5320):1848-50.
  • Toker A, Cantley LC.Signalling through the lipid products of phosphoinositide-3-OH kinase.Nature. 1997 Jun 12;387(6634):673-6.
  • Grabs D, Slepnev VI, Songyang Z, David C, Lynch M, Cantley LC, De Camilli P.The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence.J Biol Chem. 1997 May 16;272(20):13419-25.
  • Wong K, Meyers ddR , Cantley LC.Subcellular locations of phosphatidylinositol 4-kinase isoforms.J Biol Chem. 1997 May 16;272(20):13236-41.
  • Derman MP, Toker A, Hartwig JH, Spokes K, Falck JR, Chen CS, Cantley LC, Cantley LG.The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C.J Biol Chem. 1997 Mar 7;272(10):6465-70.
  • Franke TF, Kaplan DR, Cantley LC.PI3K: downstream AKTion blocks apoptosis.Cell. 1997 Feb 21;88(4):435-7.
  • Meyers R, Cantley LC.Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase.J Biol Chem. 1997 Feb 14;272(7):4384-90.
  • Franke TF, Kaplan DR, Cantley LC, Toker A.Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.Science. 1997 Jan 31;275(5300):665-8.
  • Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, Crompton A, Chan AC, Anderson JM, Cantley LC.Recognition of unique carboxyl-terminal motifs by distinct PDZ domains.Science. 1997 Jan 3;275(5296):73-7.
  • Fruman DA, Cantley LC, Carpenter CL.Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene.Genomics. 1996 Oct 1;37(1):113-21.
  • Panchamoorthy G, Fukazawa T, Miyake S, Soltoff S, Reedquist K, Druker B, Shoelson S, Cantley L, Band H.p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase.J Biol Chem. 1996 Feb 9;271(6):3187-94.